Endoscopic submucosal dissection as minimally invasive treatment for superficial pharyngeal cancer: a phase II study (with video).

摘要: Background and Aims Although endoscopic submucosal dissection (ESD) has been applied for superficial pharyngeal cancer, no prospective trials have reported. To investigate the efficacy safety of ESD we conducted a phase II trial. Methods Fifty-four patients with 73 lesions were enrolled from September 2010 to August 2014, was performed. The primary endpoint complete resection rate. Secondary endpoints safety, recurrence-free survival, overall incidence metachronous cancer. Results had stage 0-III cancer: 0, n = 22; I, 14; II, 17; III, 1. en bloc rate 100%, 79.5% (58/73 lesions; 95% confidence interval, 68%-88%). No serious adverse events related encountered. Four required nasogastric intubation feeding. percutaneous gastrostomy tracheotomy. Swallowing, speech, airway functions preserved in all patients. One 54 died an unrelated illness. Median follow-up 27 months (range 6-55 months). Local cervical lymph node metastasis observed 1 patient, case salvaged successfully dissection. 3-year survival rates 97.7% 98.1%, respectively. Cumulative development multiple cancers pharynx at 3 years 18.4%. Conclusions appears be safe effective minimally invasive treatment (Clinical trial registration number: UMIN000003623.)